# Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda

> **NCT04336189** · PHASE3 · COMPLETED · sponsor: **Grant Dorsey, M.D, Ph.D.** · enrollment: 2757 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Sulfadoxine-pyrimethamine (SP)
- **DRUG:** Dihydroartemisinin-piperaquine (DP)

## Key facts

- **NCT ID:** NCT04336189
- **Lead sponsor:** Grant Dorsey, M.D, Ph.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-28
- **Primary completion:** 2024-07-28
- **Final completion:** 2024-07-28
- **Target enrollment:** 2757 (ACTUAL)
- **Last updated:** 2025-11-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04336189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04336189, "Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04336189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*